onclive· 2mo ago
save<![CDATA[Darolutamide Plus ADT Yields Significant OS Benefit in mHSPC]]>
May 15, 2026read original ↗
<![CDATA[Darolutamide plus ADT demonstrated a 50% reduction in the risk of death in metastatic hormone-sensitive prostate cancer.]]>
The original article is no longer reachable from this URL.
read full article on onclive ↗🔗 mentioned in this article
no entities indexed yet
comments(0)
5-min edit window · permanent after that